Product Information
DAPTOMYCIN 500 MG VIAL is a generic product labeled by Hikma Pharmaceuticals USA Inc., priced at $23.7984 per EA under NDC 00143944401. Its NADAC has been published 44 times since Dec 3, 2025.
FDA first approved this application on Jun 15, 2016. Its Orange Book therapeutic-equivalence code is AP.
Strength
500 mg/10mL
Manufacturer
Hikma Pharmaceuticals USA Inc.NDC
00143944401
Classification
Generic
Dosage Form
INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION
Route
INTRAVENOUS
Effective Date
9/23/2026
Active Ingredients
DAPTOMYCINApproval Type
Generic (ANDA)
FDA Application
ANDA206005FDA Approved
6/15/2016
TE Code
AP
On Market Since
9/30/2025
Pharmacological Classes
Price Statistics
The NADAC for DAPTOMYCIN 500 MG VIAL has been published 44 times since Dec 3, 2025, and over the history we have for it it has risen 18.4%. The table below summarizes its recorded NADAC range and movement.
| Current price | $23.7984 per EA |
|---|---|
| All-time high | $23.7984 (Sep 30, 2026) |
| All-time low | $20.1020 (Dec 3, 2025) |
| 52-week high | $23.7984 |
| 52-week low | $20.1020 |
| Median price | $20.8350 |
| Average price | $21.3258 |
| Largest weekly change | +8.9% (Aug 19, 2026) |
| Weeks tracked | 44 |
| Tracking since | Dec 3, 2025 |
Generic Alternatives
The matcher finds 12 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 13% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Hikma Pharmaceuticals USA Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Daptomycin market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Lipopeptide Antibacterial class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of DAPTOMYCIN 500 MG VIAL?
The current National Average Drug Acquisition Cost (NADAC) for DAPTOMYCIN 500 MG VIAL, manufactured by Hikma Pharmaceuticals USA Inc., is $23.7984 per EA (NDC 00143944401), effective Sep 30, 2026.
How has the price of DAPTOMYCIN 500 MG VIAL changed over time?
Over the history we have for it, the NADAC for DAPTOMYCIN 500 MG VIAL has risen 18.4%. It has been tracked across 44 weekly CMS publications since Dec 3, 2025.
What are the highest and lowest recorded NADAC prices for DAPTOMYCIN 500 MG VIAL?
Since Dec 3, 2025, the NADAC for DAPTOMYCIN 500 MG VIAL has ranged from a low of $20.1020 (Dec 3, 2025) to a high of $23.7984 (Sep 30, 2026), with a median of $20.8350 per EA.
Are there cheaper alternatives to DAPTOMYCIN 500 MG VIAL?
Yes. 12 manufacturers publish a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, DAPTOMYCIN 500 MG VIAL, is $20.7686 per EA — about 13% below DAPTOMYCIN 500 MG VIAL.
Who manufactures DAPTOMYCIN 500 MG VIAL?
DAPTOMYCIN 500 MG VIAL (NDC 00143944401) is labeled by Hikma Pharmaceuticals USA Inc., and CMS classifies it as a generic product.